To: Insurance Plans/Issuers
In the response to have increased testing capacity renegade.bio’s high throughput technology, faster resulting and more effective response to the COVID-19 pandemic, the Centers for Medicare and Medicaid Services has issued additional coding and pricing guidance for certain clinical diagnostic laboratory tests for the detection of SARS-CoV-2 or the diagnosis of the virus that causes COVID-19 (COVID-19 testing). CMS Ruling No. CMS-2020-01-R dated April 14, 2020, CMS advised that COVID-19 testing utilizing high-throughput technology should be identified by two new HCPCS Codes U0003 or U0004. The appropriate code for the testing we perform is U0003 and this code should be paid at $100.00.
Renegade.bio will accept reimbursement at 100% of the CMS 2020 National Limitation Amount for the 2019 Novel Coronavirus (COVID-19), NAA test (Lab 144A/ U0003), which is now $100.00.
Renegade.bio’s mission is accelerating humanity’s capacity to test for Novel pathogens such as COVID-19. Our work empowers an overburdened public health system to respond swiftly to epidemiologic crises by delivering fast, reliable, cost-effective solutions for community-based triage.